Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

(p<0.0001)

0.34

(72% reduction)

(p<0.0001)Key secondary endpointsProportion of patients with greater than or equal to 1 flare (% reduction compared to placebo) 56.1%

25.6%

(54% reduction)

(p=0.0001)

20.5%

(63% reduction)

(p<0.0001)Proportion of patients with  greater than or equal to 2 flares (% reduction compared to placebo)32.9%

8.5%

(74% reduction)

(p=0.0002)

6.0%

(82% reduction)

(p<0.0001)* One patient did not report flare data and was excluded from efficacy analyses Overall, the cumulative rate of infections was 27.4% in patients treated with ARCALYST 160 mg, 28.0% in patients treated with ARCALYST 80 mg, and 25.6% in placebo patients.  No deaths were reported in this study.

Specific adverse events that occurred at a frequency of at least 5% in any study group were: injection site reaction (17.9% with ARCALYST 160 mg, 12.2% with ARCALYST 80 mg, and 1.2% with placebo), upper respiratory tract infection (15.5% with ARCALYST 160 mg, 12.2% with ARCALYST 80 mg, and 12.2% with placebo), influenza viral infection (6.0% with ARCALYST 160 mg, 6.1% with ARCALYST 80 mg, and 7.3% with placebo), taking more than the recommended dose (4.8% with ARCALYST 160 mg, 7.3% with ARCALYST 80 mg, and 2.4% with placebo), and headache (1.2% with ARCALYST 160 mg, 6.1% with ARCALYST 80 mg, and 3.7% with placebo).

About the PRE-SURGE 1 StudyRegeneron previously announced the results of the identical North American-based PRE-SURGE 1 (PREventative Study against URate-lowering drug-induced Gout Exacerbations) study, a double-blind, placebo-controlled study which evaluated the number of gout flares per patient over the first 16 weeks following initiation of allopurinol therapy.  Patients who received ARCALYST at a weekly, self-administered, subcutaneous dose of 160 mg had an 80% decrease in mean numbe
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: ... appointed Charles J. (Chuck) Bramlage and Dr. ... Board.  Mr. Bramlage is a veteran ... and other commercial functions.  He is currently the Chief ... company that was recently acquired by AstraZeneca and is ...
(Date:7/22/2014)... July 22, 2014  Pressure BioSciences, Inc. ... Parabase Genomics ("Parabase"), (together "the companies"), today ... research and development agreement (the "collaboration"). Under ... develop a front-end, sample preparation method for ... confirmatory testing process. The sample preparation method ...
(Date:7/22/2014)... Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today the addition of ... to the Board of Directors. QMC also announced formation of a ... Chief Science Officer and Board of Directors Member, along with Scientific ... and Mr. Tomio Gotoh , a pioneer of the Personal ... Quantum Materials welcomes two new outside Board members, Mr. ...
Breaking Medicine Technology:BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 2BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 3BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 4BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 5BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 6BioDelivery Sciences Appoints Charles J. Bramlage and Dr. Barry I. Feinberg to its Board of Directors 7Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 2Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 3Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics' Targeted Next Generation Sequencing Testing Platform 4Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... YORK, Oct. 14 Reportlinker.com announces that a ... catalogue: Colorectal Cancer - France ... http://www.reportlinker.com/p0312710/Colorectal-Cancer---France-Drug-Forecasts-and-Treatment-Analysis-to-2020.html ... Analysis to 2020 SummaryGlobalData, the ...
... Oct. 14 Cumberland Pharmaceuticals Inc. (Nasdaq: ... today announced that Acetadote® ( acetylcysteine ) Injection, ... is now commercially available in the Australian market. Phebra ... exclusive license from U.S.-based Cumberland Pharmaceuticals to market and ...
Cached Medicine Technology:Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 14Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020 15Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia 5
(Date:7/22/2014)... 22, 2014 Air Conditioning & Heating ... an authorized Daikin comfort pro dealer. This means that ... heating and cooling system equipment. Only a select few ... reviewed before being approved. , Daikin co-developed an R-410A ... Split System Air Conditioning Market. They are also the ...
(Date:7/22/2014)... 2014 United Benefit Advisors (UBA), the ... Les McPhearson, an insurance veteran with more than 15 ... and be based in the company's Chicago office. , ... that Les chose to accept this important, strategic position ... the many challenges facing UBA and its Partners as ...
(Date:7/22/2014)... By Steven Reinberg ... -- Women who are obese during pregnancy may be more ... new review suggests. "We found that, compared with children ... overweight or obese during pregnancy had up to 20 to ... Erick Forno, an assistant professor of pediatrics at Children,s Hospital ...
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... pretext for multinational corporations to take control of the precious ... With sales of over $35 billion worldwide in the ... buy up pristine springs in some of the country's most ... one-third of the U.S. market and sells 70 different brand ...
... overdose during pregnancy could be harmful, according to an Iranian ... combat anemia in pregnancy but many women take extra iron. ... carry enough oxygen due to low number of red blood ... carry normal amounts of oxygen. Common symptoms of anemia include ...
... for Inclusive Communities (CAIC) has recently joined the fight ... the majority of state and national disability rights organizations ... group that works on behalf of groups with developmental ... as a new national AP/Ipsis poll was released indicating ...
... the Pharmaceutical Research and Manufacturers of America (PhRMA) finds ... of the three leading causes of death of Americans ... currently in clinical trials or under review by the ... and stroke are still leading causes of death in ...
... advent of a possible new blockbuster drug and greater ... drug addictions, global sales of smoking cessation and ... little over $1.1 billion in 2005 to more than ... Addiction Treatments: A World Market Analysis, a new study ...
... on cardiometabolic risk factors beyond those expected from weight ... not be due to the drug itself, reports an ... Bulletin (DTB). ,Advertisements for rimonabant (sold ... an estimated 50% of the effects on cardiometabolic ...
Cached Medicine News:Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: